Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Inositol in the MAnaGemENt of abdominal aortic aneurysm (IMAGEN): Study protocol for a randomised controlled trial
Vise andre og tillknytning
2017 (engelsk)Inngår i: Trials, ISSN 1745-6215, E-ISSN 1745-6215, Vol. 18, nr 1, artikkel-id 547Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Background: An abdominal aortic aneurysm (AAA) is a focal dilation of the abdominal aorta and is associated with a risk of fatal rupture. Experimental studies suggest that myo-inositol may exert beneficial effects on AAAs through favourable changes to biological pathways implicated in AAA pathology. The aim of the Inositol in the MAnaGemENt of abdominal aortic aneurysm (IMAGEN) trial is to assess if myo-inositol will reduce AAA growth. Methods/design: IMAGEN is a multi-centre, prospective, parallel-group, randomised, double-blind, placebo-controlled trial. A total of 164 participants with an AAA measuring ≥ 30 mm will be randomised to either 2 g of myo-inositol or identical placebo twice daily for 12 months. The primary outcome measure will be AAA growth estimated by increase in total infrarenal aortic volume measured on computed tomographic scans. Secondary outcome measures will include AAA diameter assessed by computed tomography and ultrasound, AAA peak wall stress and peak wall rupture index, serum lipids, circulating AAA biomarkers, circulating RNAs and health-related quality of life. All analysis will be based on the intention-to-treat principle at the time of randomisation. All patients who meet the eligibility criteria, provide written informed consent and are enrolled in the study will be included in the primary analysis, regardless of adherence to dietary allocation. Discussion: Currently, there is no known medical therapy to limit AAA progression. The IMAGEN trial will be the first randomised trial, to our knowledge, to assess the value of myo-inositol in limiting AAA growth.

sted, utgiver, år, opplag, sider
BioMed Central Ltd. , 2017. Vol. 18, nr 1, artikkel-id 547
Emneord [en]
Abdominal aortic aneurysm, Clinical trial, Inositol, lipid, placebo, adult, Article, computer assisted tomography, controlled study, diet supplementation, double blind procedure, human, intention to treat analysis, lipid blood level, major clinical study, multicenter study, parallel design, patient compliance, prospective study, quality of life, randomized controlled trial, treatment outcome
HSV kategori
Identifikatorer
URN: urn:nbn:se:kth:diva-227143DOI: 10.1186/s13063-017-2304-xISI: 000415326200002PubMedID: 29145894Scopus ID: 2-s2.0-85034117324OAI: oai:DiVA.org:kth-227143DiVA, id: diva2:1202986
Merknad

QC 20180502

Tilgjengelig fra: 2018-05-02 Laget: 2018-05-02 Sist oppdatert: 2019-02-07bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstPubMedScopus

Søk i DiVA

Av forfatter/redaktør
Gasser, T. Christian
Av organisasjonen
I samme tidsskrift
Trials

Søk utenfor DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 27 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf